Catalog No.
DHB63201
Expression system
Mammalian Cells
Species reactivity
Human
Isotype
Fusion - [ACVRL1 (activin A receptor like type 1, activin receptor-like kinase 1, ACVRLK1, ALK1, ALK-1, serine/threonine-protein kinase receptor R3, SKR3, HHT, HHT2, ORW2)]2 - IGHG1 Fc (Fragment constant)
Target
BMP-10, Bone morphogenetic protein 10, BMP10, GDF2, BMP-9, Growth/differentiation factor 2, Bone morphogenetic protein 9, GDF-2, BMP9
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
O95393 & Q9UK05
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
ACE-041, CAS: 1186210-24-1
Clone ID
Dalantercept
Advancements in TGF-β Targeting Therapies for Head and Neck Squamous Cell Carcinoma., PMID:39272905
Targeting the Transforming Growth Factor-beta Signaling Pathway in the Treatment of Gynecologic Cancer., PMID:35747971
Strengthening the FDA's Enforcement of ClinicalTrials.gov Reporting Requirements., PMID:34766971
Clinicopathological features and resistance mechanisms in HIP1-ALK-rearranged lung cancer: A multicenter study., PMID:34687488
Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations., PMID:32616076
A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma., PMID:30951193
A Phase Ib, Open-Label Study of Dalantercept, an Activin Receptor-Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma., PMID:30352941
Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study., PMID:30041929
The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma., PMID:28031424
A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck., PMID:27648727
Targeting tumour vasculature by inhibiting activin receptor-like kinase (ALK)1 function., PMID:27528762
Regulation of the ALK1 ligands, BMP9 and BMP10., PMID:27528761
Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma., PMID:27248821
Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors., PMID:26373572
Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229N., PMID:25888978
Activin receptor inhibitors--dalantercept., PMID:25708802
New agents and new targets for renal cell carcinoma., PMID:24857106
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer., PMID:24173543
ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth., PMID:20124460
For research use only. Not for human or drug use.
